Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06333652
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-03-20
Brief Title:
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis Elevated Liver enzymes Low Platelets HELLP syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None